RT Journal Article
SR Electronic
T1 MANAGEMENT OF DIFFERENTIATED THYROID CANCER: THE STANDARD OF CARE
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.121.262402
DO 10.2967/jnumed.121.262402
A1 Anca M. Avram
A1 Katherine Zukotynski
A1 Helen Ruth Nadel
A1 Luca M Giovanella
YR 2021
UL http://jnm.snmjournals.org/content/early/2021/08/19/jnumed.121.262402.abstract
AB In the past decade the management of differentiated thyroid cancer (DTC) underwent a paradigm shift towards the use of risk-stratification with the goal of maximizing benefit and minimizing morbidity of radioiodine (131I) therapy. 131I therapy is guided by information derived from surgical histopathology, molecular markers, postoperative diagnostic radioiodine scintigraphy and thyroglobulin (Tg) levels. 131I is used for diagnostic imaging and therapy of DTC based on physiologic sodium-iodine symporter expression in normal and neoplastic thyroid tissue. We summarize the essential information at the core of multidisciplinary DTC management, which emphasizes individualization of 131I therapy according to the patient’s risk for tumor recurrence.